Ryan Crisman

Biotech junkie (co-founder of Umoja Biopharma) and brewery owner (Long Table Brewhouse). Thoughts are my own.

[Ryan Crisman @crisman_ryan]

@bradloncar Swing by Colorado on your way to Texas. We can talk the sneaky good biotech growing on the front range over a hike.

[Umoja Biopharma @UmojaBiopharma]

We are excited to announce the opening of our new development and manufacturing facility, The CLIMB, in Louisville, CO. The facility will help accelerate the development of our therapeutic candidates. Read more in our press release: https://t.co/q6bn7UJi0F

[Ryan Crisman @crisman_ryan]

As soon as the cells are taken out of the body it’s a negative equation.

[Umoja Biopharma @UmojaBiopharma]

Our CEO, @andyscharenberg, joined @Erin_Harris1 for the latest episode of the #CellAndGenePodcast. Listen to learn about our lentiviral vector manufacturing facility called The CLIMB and our approach to developing next generation #immunotherapies: https://t.co/KUpBYTnKIo

[Alliance for Regenerative Medicine (ARM) @alliancerm]

New data shows that in vivo CAR-T cell therapies have the potential to unlock a new class of therapeutics. Researchers hope this technique will reduce the cost and complexity of administering CAR-Ts and broaden their application. #celltherapy
https://t.co/o1lW0wZ2Fa

[Vali Barsan, MD 🇺🇸 @vbarsan]

Umoja's: best-in-class in vivo CAR T therapy shows positive first signs https://t.co/UKBh0xPLvS

[Umoja Biopharma @UmojaBiopharma]

Today at the @CAR_TCell Summit, we presented data from our ongoing NHP study of our VivoVec™ platform, which includes the rapid, durable #CARTcell generation in vivo after a single infusion of #VivoVec particles. Learn more: https://t.co/9OAMRm6EgK #CARTCR #immunotherapy

[Umoja Biopharma @UmojaBiopharma]

We are looking forward to presenting at the upcoming 8th @CAR_TCell Summit on September 1 in Boston. Our EVP, Byoung Ryu, PhD, will share data from our ongoing non-human primate study for the first time. Find details here: https://t.co/5QuHst75GL #CARTCR #immunotherapy

[Andrew Scharenberg @andyscharenberg]

At Umoja, we made the strategic decision to bring manufacturing in-house early on with The CLIMB, allowing us to gain control of our supply chain. Shorter lead times, enhanced R&D, & seamless scalability will be game changers for us. Read more here: https://t.co/jPHHdTASCn

[Umoja Biopharma @UmojaBiopharma]

We are proud to share that our COO, David Fontana, PhD, will be presenting Umoja's mission, pipeline & technology at @IAmBiotech BIO International Convention on June 7 at 4:30 pm ET. Check out our press release for details: https://t.co/zRdy0wQW1l #BIO2023 #StandUpForScience

[Umoja Biopharma @UmojaBiopharma]

We are presenting new preclinical data at @ASGCTherapy’s #ASGCT23 that demonstrates the potent in vivo #CART cell generation and durable anti-tumor activity of our #VivoVec, #RACR, and #TumorTag platforms. Check out our presentation highlights: https://t.co/5z3X5WQowV

[Umoja Biopharma @UmojaBiopharma]

We are excited to announce we will be presenting new in vivo #CART data at the 26th @ASGCTherapy Annual Meeting. Learn more about our oral and poster presentations here: https://t.co/yGBt6zyczZ #ASGCT23

[Umoja Biopharma @UmojaBiopharma]

In this second @OutsourcedPharm article with @Louis_Garguilo our CEO @andyscharenberg and CTO @crisman_ryan discuss Umoja’s focus on bringing our therapeutics into clinical application and why we chose Colorado for the location of The CLIMB. Read here: https://t.co/Ne7ioAxCSl

[Andrew Scharenberg @andyscharenberg]

I’m pleased to have the opportunity to highlight Umoja’s in vivo CAR T cell technology at this year’s #IO360. Many patients don’t respond to current immunotherapies, and we believe our approach may help bring transformative treatments to patients.

[Ryan Crisman @crisman_ryan]

I am now scheduling out my #JPM24 if anybody is interested in meeting up. #JPM23

[Umoja Biopharma @UmojaBiopharma]

In this @pharmasalmanac Q&A, our VP and Head of Immunology Ryan Larson, PhD, discusses how Umoja’s talented team and differentiated technology platforms aim to overcome major challenges in the current cell and #GeneTherapy space. Read more here: https://t.co/00yHCD7p4o

[Umoja Biopharma @UmojaBiopharma]

We are excited to be presenting at @jpmorgan’s #JPM2023 next week! We are looking forward to sharing Umoja’s vision with our industry peers and the investment community. Read our full press release for more details: https://t.co/ms8hAWpbx3

[Umoja Biopharma @UmojaBiopharma]

We have entered a research agreement with IASO Biotherapeutics to bring together our iCIL platform with IASO’s chimeric antigen receptors to create next-generation cell therapies for #AML and other hematological malignancies. Read more: https://t.co/NuoiFVSN81 #OffTheShelf

[Umoja Biopharma @UmojaBiopharma]

We are excited to present three posters at @sitcancer from November 11-14. We will share updates on our complementary cell therapy platforms for in vivo CAR T cell therapies and #RACR-induced cytotoxic lymphocytes (#iCIL). Read our press release: https://t.co/sTfNbt4OZw #SITC2022

[Ryan Crisman @crisman_ryan]

@UmojaBiopharma A special team, game-changing platform, and inspiring place to live. Come join us!

[Ryan Crisman @crisman_ryan]

Setting my goddaughter up for lifelong love of running #hoka